Support Your Metabolism with Clinically-Studied Ingredients

Mitolyn — 6 plant-based nutrients to boost mitochondrial health, energy & natural fat burning.

★★★★★ 127,000+ customers · 90-day money-back guarantee

Dr. John Puetz, MD

Pediatrics Bridgeton, MO Male

NPI: 1508811068

Total Payments

$10,608

2018 Payments

$10,608

Companies

Transactions

Payment Breakdown by Category

Research$10,608 (100.0%)

Payments by Nature

Nature of Payment	Amount	Transactions	Share
Unspecified	$10,608	13	100.0%

Top Paying Companies

Company	Total	Records	Latest Year
BIOVERATIV THERAPEUTICS INC.	$10,608	13	$0 (2018)

Payment History by Year

Year	Amount	Transactions	Top Company
2018	$10,608	13	BIOVERATIV THERAPEUTICS INC. ($10,608)

All Payment Transactions

13 individual payment records from CMS Open Payments

Date	Company	Product	Nature	Form	Amount	Type
08/03/2018	BIOVERATIV THERAPEUTICS INC.	ELOCTATE (Drug)	—	Cash or cash equivalent	$250.00	Research
Study: An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A • Category: HEMATOLOGY
07/05/2018	BIOVERATIV THERAPEUTICS INC.	ELOCTATE (Drug)	—	Cash or cash equivalent	$1,200.00	Research
Study: An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A • Category: HEMATOLOGY
07/03/2018	BIOVERATIV THERAPEUTICS INC.	ALPROLIX (Drug)	—	Cash or cash equivalent	$1,000.00	Research
Study: Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B • Category: HEMATOLOGY
07/03/2018	BIOVERATIV THERAPEUTICS INC.	ALPROLIX (Drug)	—	Cash or cash equivalent	$503.00	Research
Study: Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B • Category: HEMATOLOGY
06/07/2018	BIOVERATIV THERAPEUTICS INC.	ALPROLIX (Drug)	—	Cash or cash equivalent	$1,000.00	Research
Study: Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B • Category: HEMATOLOGY
06/06/2018	BIOVERATIV THERAPEUTICS INC.	ELOCTATE (Drug)	—	Cash or cash equivalent	$987.00	Research
Study: Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A • Category: HEMATOLOGY
06/06/2018	BIOVERATIV THERAPEUTICS INC.	ELOCTATE (Drug)	—	Cash or cash equivalent	$987.00	Research
Study: Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A • Category: HEMATOLOGY
05/14/2018	BIOVERATIV THERAPEUTICS INC.	ELOCTATE (Drug)	—	Cash or cash equivalent	$166.00	Research
Study: An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A • Category: HEMATOLOGY
04/03/2018	BIOVERATIV THERAPEUTICS INC.	ELOCTATE (Drug)	—	Cash or cash equivalent	$1,265.00	Research
Study: An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A • Category: HEMATOLOGY
04/03/2018	BIOVERATIV THERAPEUTICS INC.	ELOCTATE (Drug)	—	Cash or cash equivalent	$1,050.00	Research
Study: An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A • Category: HEMATOLOGY
04/03/2018	BIOVERATIV THERAPEUTICS INC.	ELOCTATE (Drug)	—	Cash or cash equivalent	$1,000.00	Research
Study: An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A • Category: HEMATOLOGY
04/03/2018	BIOVERATIV THERAPEUTICS INC.	ELOCTATE (Drug)	—	Cash or cash equivalent	$900.00	Research
Study: An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A • Category: HEMATOLOGY
04/03/2018	BIOVERATIV THERAPEUTICS INC.	ELOCTATE (Drug)	—	Cash or cash equivalent	$300.00	Research
Study: An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A • Category: HEMATOLOGY

Research Studies & Clinical Trials

Study Name	Company	Amount	Records
An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A	BIOVERATIV THERAPEUTICS INC.	$6,131	8
Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B	BIOVERATIV THERAPEUTICS INC.	$2,503	3
Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A	BIOVERATIV THERAPEUTICS INC.	$1,974	2

About Dr. John Puetz, MD

Dr. John Puetz, MD is a Pediatrics healthcare provider based in Bridgeton, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1508811068.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Puetz, MD has received a total of $10,608 in payments from pharmaceutical and medical device companies, with $10,608 received in 2018. These payments were reported across 13 transactions from 1 company. The most common payment nature is "" ($10,608).

16,000 Woodworking Plans

Step-by-step blueprints for any project. Beginner to expert.

Detailed schematics Cutting lists & materials Lifetime access — $67

★★★★★ 60-day guarantee

Get Instant Access

Practice Information

Specialty Pediatrics
Location Bridgeton, MO
Active Since 05/23/2006
Last Updated 10/30/2020
Taxonomy Code 208000000X
Entity Type Individual
NPI Number 1508811068

Products in Payments

ELOCTATE (Drug) $8,105
ALPROLIX (Drug) $2,503

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.